Melbourne, Australia & Indianapolis, USA – 20 February 2025 – Telix Pharmaceuticals (ASX: TLX, Nasdaq: TLX) has wrapped up a record-breaking year, delivering strong financial growth while laying the foundation for an even bigger 2025. Revenue surged 56% to $783.2 million, fueled by booming sales of its flagship prostate cancer imaging agent, Illuccix®. This result exceeded the company’s full-year guidance and marked Telix’s second consecutive year of profitability, despite significant investments in research and global expansion.
With $194.6 million directed toward R&D, Telix focused heavily on advancing late-stage assets, preparing for the 2025 launch of three new imaging products—Gozellix®, Pixclara®, and Zircaix®—while also expanding its global supply chain. Strategic acquisitions, including ARTMS, IsoTherapeutics, and RLS (USA), further strengthened the company’s ability to scale manufacturing and distribution.
Group CEO Dr. Christian Behrenbruch sees 2025 as a transformational year for the company. “This has been an extraordinary year for Telix, not just in financial performance but in setting up our business for the next stage of growth. With multiple product launches ahead and an expanding international footprint, we are making major strides toward our mission of ensuring global patient access to precision medicine.”
The numbers tell the story of a business hitting its stride. Adjusted EBITDA climbed 70% to $99.3 million, while operating profit soared to $82.1 million, a staggering 423% increase from last year. Profit after tax skyrocketed 860% to $49.9 million, highlighting the company’s ability to balance growth with profitability.
Looking ahead, Telix has set ambitious guidance for FY2025, projecting revenue between $1.18 billion and $1.23 billion—marking a significant leap from 2024. This forecast includes continued growth for Illuccix® and contributions from the newly acquired RLS business. Meanwhile, R&D investment is set to rise by 20% to 25% as the company doubles down on late-stage therapeutic trials and next-generation pipeline advancements.
With a robust financial position, a deep pipeline of precision medicine innovations, and a clear strategy for global expansion, Telix is poised for another blockbuster year in 2025.
